Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

The global sales of ophthalmic lasers are estimated to be worth USD 976.8 million in 2024 and are anticipated to reach a value of USD 1,561.0 million by 2034. Sales are projected to rise at a CAGR of ...

According to the Ministry of Health and Welfare's National Health and Nutrition Survey, the prevalence of diabetes in 2023 ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Aim Retinal oxygen metabolism is thought to be affected in diabetic retinopathy. The aim of this study was to test whether retinal vessel oxygen saturation is different in patients with diabetic ...

Fear is a natural response when something threatens your vision—but it’s also a signal to act quickly. Some retinal ...

Telangiectatic capillaries may have potential clinical relevance for diagnosis and treatment of diabetic macular edema.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...